Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Keldahl

Surgery Chicago, IL Medical Doctor

NPI 1114181658 CMS profile 277593

3000 N. Halsted St., Suite 703, Chicago, IL 60657

Open in the dashboard

General payments

$764,578

258 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Keldahl of Chicago, IL is reported in the CMS Open Payments database as having received $764,578 across 258 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $137,054 40
2024 General $132,925 45
2023 General $118,792 35
2022 General $110,346 47
2021 General $94,475 18
2020 General $77,444 33
2019 General $93,542 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Keldahl
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Mark Keldahl were reported at $137,054. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Mark Keldahl Surgery median Middle half National median
2019 $93,542 $253 $82–$1,521 $163
2020 $77,444 $131 $40–$706 $114
2021 $94,475 $168 $50–$904 $132
2022 $110,346 $224 $76–$1,218 $149
2023 $118,792 $253 $82–$1,255 $160
2024 $132,925 $279 $90–$1,381 $164
2025 $137,054 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. LeMaitre Vascular, Inc. $747,872 97 payments
  2. AngioDynamics, Inc. $7,918 56 payments
  3. Abbott Laboratories $4,260 59 payments
  4. Inari Medical, Inc. $2,195 14 payments
  5. W. L. Gore & Associates, Inc. $372 2 payments
  6. Stryker Corporation $355 5 payments
  7. LimFlow Inc. $341 2 payments
  8. Medtronic, Inc. $261 3 payments
  9. Janssen Pharmaceuticals, Inc $173 2 payments
  10. Bard Peripheral Vascular, Inc. $170 1 payment
  11. Other $660 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $747,605 87 payments
  2. Food and Beverage $10,619 150 payments
  3. Travel and Lodging $6,355 21 payments
Products named General payments · program years 2019–2025
  1. RESTOREFLOW $354,283 47 payments
  2. RESTOREFLO $260,912 38 payments
  3. HYDRO LEMAITRE VALVULOTOME $132,677 12 payments
  4. AURYON LASER SYSTEM 100-120 VAC Pad $4,362 48 payments
  5. Omnilink Elite vascular stent system $2,438 20 payments
  6. CT THROMBECTOMY SYSTEM KIT $1,893 11 payments
  7. FLOWTRIEVER CATHETER, S $1,893 11 payments
  8. ANGIOVAC $1,781 2 payments
  9. ALPHAVAC $884 4 payments
  10. Auryon Laser System 100-120 Vac Et $819 1 payment
  11. Other $5,303 85 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

94

Median for Vascular Surgery: 122

Drug cost

$26,883

Median for Vascular Surgery: $14,135

Branded share of claims

100%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 26 $26,440
Clopidogrel Clopidogrel Bisulfate Brand 54 $306
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 14 $137

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$96,966

Medicare's payments for the services billed

Medicare patients

365

Average age 75

Services billed

1,124

168 women, 197 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 53%
Diabetes 52%
Chronic kidney disease 45%
Heart failure 39%
Atrial fibrillation 30%
COPD 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

258 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record